Hemostemix (HEM) Stock Chart & Stock Price History → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free HEM Stock Alerts C$0.04 0.00 (0.00%) (As of 05/17/2024 02:59 PM ET) Add Compare Share Share ChartStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Hemostemix Stock Price Performance5 Day Performance0.00%1 Month Performance-20.00%3 Month Performance-46.67%6 Month Performance-42.86%Year-To-Date Performance-42.86%1 Year Performance-70.37% Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter Email Address Ad InvestorPlaceBoost your retirement with these AI payoutsBREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. HEM Stock Chart for Monday, May, 20, 2024 HEM Chart by TradingView Hemostemix Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/17/2024C$0.04C$0.04C$0.04C$0.0423,000 shsC$3.59 million05/16/2024C$0.04C$0.04C$0.05C$0.04157,250 shsC$3.59 million05/15/2024C$0.04C$0.04C$0.05C$0.04157,250 shsC$3.59 million05/14/2024C$0.04C$0.04C$0.04C$0.04250,000 shsC$3.59 million05/13/2024C$0.04C$0.04C$0.04C$0.0470,000 shsC$3.59 million05/10/2024C$0.04C$0.04C$0.04C$0.04100,000 shsC$3.59 million Get the Latest News and Ratings for HEM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. 05/09/2024C$0.04C$0.04C$0.04C$0.04104,700 shsC$3.59 million05/08/2024C$0.04C$0.04C$0.04C$0.04104,700 shsC$3.59 million05/07/2024C$0.04C$0.04C$0.05C$0.04103,000 shsC$3.59 million05/06/2024C$0.04C$0.04C$0.04C$0.0428,000 shsC$3.59 million05/03/2024C$0.04C$0.04C$0.05C$0.0491,000 shsC$3.59 million05/02/2024C$0.04C$0.04+14.29%C$0.04C$0.0443,000 shsC$3.59 million05/01/2024C$0.04C$0.04-12.50%C$0.04C$0.0497,777 shsC$3.14 million04/30/2024C$0.04C$0.04C$0.04C$0.0457,000 shsC$3.59 million04/29/2024C$0.05C$0.04-11.11%C$0.04C$0.045,000 shsC$3.59 million04/26/2024C$0.04C$0.05+12.50%C$0.05C$0.0432,000 shsC$4.04 million04/25/2024C$0.05C$0.04-11.11%C$0.05C$0.04353,200 shsC$3.59 million04/24/2024C$0.05C$0.05-10.00%C$0.05C$0.0482,500 shsC$4.04 million04/23/2024C$0.05C$0.05C$0.05C$0.0520,000 shsC$4.49 million04/22/2024C$0.05C$0.05C$0.05C$0.0520,000 shsC$4.49 million04/19/2024C$0.05C$0.05C$0.05C$0.05111,000 shsC$4.49 million04/18/2024C$0.06C$0.05-9.09%C$0.05C$0.0516,000 shsC$4.49 million04/17/2024C$0.06C$0.06C$0.06C$0.064,200 shsC$4.94 million04/16/2024C$0.06C$0.06C$0.06C$0.0640,000 shsC$4.94 million04/15/2024C$0.06C$0.06C$0.06C$0.065,000 shsC$4.94 million04/12/2024C$0.06C$0.06C$0.06C$0.065,000 shsC$4.94 million04/11/2024C$0.06C$0.06C$0.06C$0.065,000 shsC$4.94 million04/10/2024C$0.06C$0.06-8.33%C$0.06C$0.0665,020 shsC$4.94 million04/09/2024C$0.06C$0.06C$0.06C$0.062,020 shsC$5.39 million04/08/2024C$0.06C$0.06C$0.06C$0.062,000 shsC$5.39 million04/05/2024C$0.07C$0.06-7.69%C$0.06C$0.062,000 shsC$5.39 million04/04/2024C$0.07C$0.07C$0.07C$0.0664,750 shsC$5.84 million04/03/2024C$0.07C$0.07C$0.07C$0.0664,750 shsC$5.84 million04/02/2024C$0.07C$0.07C$0.07C$0.0664,750 shsC$5.84 million04/01/2024C$0.07C$0.07C$0.07C$0.0664,750 shsC$5.84 million03/29/2024C$0.07C$0.07C$0.07C$0.0664,750 shsC$5.84 million03/28/2024C$0.07C$0.07C$0.07C$0.0664,750 shsC$5.84 million03/27/2024C$0.07C$0.07C$0.07C$0.0725,000 shsC$5.84 million03/26/2024C$0.06C$0.07+8.33%C$0.07C$0.0732,000 shsC$5.84 million03/25/2024C$0.07C$0.06-7.69%C$0.06C$0.0650,208 shsC$5.39 million**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!Click for Zack's full report03/22/2024C$0.06C$0.07+8.33%C$0.07C$0.071,000 shsC$5.84 million03/21/2024C$0.06C$0.06C$0.06C$0.0628,250 shsC$5.39 million03/20/2024C$0.08C$0.06-20.00%C$0.07C$0.05309,740 shsC$5.39 million03/19/2024C$0.08C$0.08C$0.08C$0.072,000 shsC$6.73 million03/18/2024C$0.07C$0.08+7.14%C$0.08C$0.0718,000 shsC$6.73 million03/15/2024C$0.07C$0.07C$0.07C$0.0718,000 shsC$6.29 million03/14/2024C$0.07C$0.07C$0.07C$0.0718,000 shsC$6.29 million03/13/2024C$0.08C$0.07-6.67%C$0.08C$0.0755,000 shsC$6.29 million03/12/2024C$0.07C$0.08+7.14%C$0.08C$0.0737,000 shsC$6.73 million03/11/2024C$0.08C$0.07-6.67%C$0.07C$0.0737,500 shsC$6.29 million03/08/2024C$0.08C$0.08-6.25%C$0.08C$0.0752,000 shsC$6.73 million03/07/2024C$0.08C$0.08C$0.09C$0.082,500 shsC$7.18 million03/06/2024C$0.08C$0.08C$0.09C$0.082,500 shsC$7.18 million03/05/2024C$0.08C$0.08C$0.09C$0.082,500 shsC$7.18 million03/04/2024C$0.08C$0.08C$0.09C$0.082,500 shsC$7.18 million03/01/2024C$0.08C$0.08C$0.08C$0.0820,000 shsC$7.18 million02/29/2024C$0.10C$0.08-15.79%C$0.08C$0.0819,036 shsC$7.18 million02/28/2024C$0.07C$0.10+35.71%C$0.10C$0.07109,333 shsC$8.53 million02/27/2024C$0.07C$0.07+7.69%C$0.07C$0.0754,000 shsC$6.29 million02/26/2024C$0.07C$0.07-7.14%C$0.08C$0.0792,000 shsC$5.84 million02/23/2024C$0.07C$0.07C$0.07C$0.0716,500 shsC$6.29 million02/22/2024C$0.08C$0.07-12.50%C$0.08C$0.0733,700 shsC$6.29 million02/21/2024C$0.08C$0.08+6.67%C$0.09C$0.0811,500 shsC$7.18 million02/20/2024C$0.08C$0.08-6.25%C$0.09C$0.0829,000 shsC$6.73 million02/19/2024C$0.08C$0.08C$0.08C$0.0831,000 shsC$7.18 million Related Companies: Quest PharmaTech Stock Price Chart Innovotech Stock Price Chart Aeterna Zentaris Stock Price Chart Aequus Pharmaceuticals Stock Price Chart Entourage Health Stock Price Chart CardioComm Solutions Stock Price Chart Titan Medical Stock Price Chart Delta 9 Cannabis Stock Price Chart Voyageur Pharmaceuticals Stock Price Chart Crescita Therapeutics Stock Price Chart Receive HEM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. This page (CVE:HEM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
